Compare Neurocrine Biosciences Inc (NBIX) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs SkyWest Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while SkyWest Inc trades at $96.26 (market cap $3.69B). The key difference: Neurocrine Biosciences Inc is far larger — about 4.3× SkyWest Inc's market cap. Which is the better fit depends on your goals.
| NBIX | SKYW | |
|---|---|---|
Market Cap | $15.77B | $3.69B |
Sector | Health | Technology |
52-Week High | $185.50 | $115.94 |
52-Week Low | $123.10 | $78.40 |
Enterprise Value | $15.78B | $5.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
SkyWest (SKYW) trades at $94.98, down 4.12% on the day, amid a bearish technical signal. The stock shows mixed earnings performance with a recent Q2 2026 miss but a Q1 beat, while maintaining solid profitability with a net margin of 9.78% and ROE of 15.34%. Valuation metrics appear attractive with a P/E of 9.44 and P/S of 0.92, below industry averages. Recent news highlights institutional interest and fleet expansion as growth drivers.
The outlook is cautiously optimistic given strong analyst support—56% buy ratings with a $112 consensus target—and robust cash flow trends. Key risks include earnings volatility, cost pressures from maintenance and fuel, and insider selling. The stock presents a value opportunity if operational execution improves, but investors should monitor quarterly results for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
